Johnson & Johnson unveils latest plan to settle ovarian cancer talc claims
MarketWatch -

The plan is expected to resolve 99.75% of all pending talc lawsuits against the company and its units in the U.S., it said in a statement.

Related Articles

Latest in News

More from MarketWatch | article_normal Pharmaceuticals Healthcare Life Sciences Consumer Products Corporate Strategy Planning Corporate Crime Legal Action Regulation Government Policy New Products Services Corporate Industrial News Corporate Organizational Restructuring Products Cancer Political General News Crime Demographic Health Health Medical Conditions Women's Health Content Types Factiva Filters C&E Executive News Filter C&E Industry News Filter Johnson & Johnson JNJ corporate strategy planning corporate crime legal action regulation government policy new products services corporate industrial news corporate organizational restructuring products cancer political general news crime demographic health health medical conditions women's health content types factiva filters c&e executive news filter c&e industry news filter pharmaceuticals healthcare life sciences consumer products Talc Ovarian cancer